Estetrol (E4) is what makes NEXTSTELLIS unique and will completely change how you think about estrogen1-3

With NEXTSTELLIS, your patients get the contraceptive efficacy they need from a combined pill, with the tolerability they want2-5

NEXTSTELLIS is the only COC to contain a NATIVE estrogen (E4):1,2,6-8

E4 circulates between the mother and fetus during pregnancy3

E4 in NEXTSTELLIS is produced from a plant source4

E4 is the first new development in contraceptive estrogen in over 60 years5

NEXTSTELLIS is the only COC to contain a SELECTIVE estrogen2

E4 is an estrogen with a unique, selective, mechanism of action1-5

E4 has LOWER potency and binding affinity than that of E2 (itself less than EE) – so NEXTSTELLIS is dosed in mg not mcg2,9

Unlike other estrogens, E4 is selective and so has different actions in different tissues1,2,4,6-8,10

Understanding the selective tissue activity of E41,3,7,9,11-16

Tap or hover over the body parts to see the effects of E4


Sex hormone binding globulin (SHBG)
Clotting factors*

*Compared with at baseline,
cycle 7, and cycle 14 in Phase 3 study


Inhibits estradiol-induced proliferation


HIGH IMPACT – good cycle control**

**Studied paired with a progestin


Maintains bone mineral density


Supports tissue maintenance


Supports tissue maintenance

Vascular system

Repairs and maintains tissue
Regulates vascular tone

woman central image woman central image woman central image woman central image woman central image woman central image woman central image


For more information on our product availability, savings program,
sampling, or for details on our patient support services.


IMPORTANT SAFETY INFORMATION FOR NEXTSTELLIS® (drospirenone and estetrol tablets 3 mg/14.2 mg)


See full prescribing information for complete boxed warning.

  • Females over 35 years old who smoke should not use NEXTSTELLIS
  • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use.



These highlights do not include all the information needed to use NEXTSTELLIS safely and effectively. See full prescribing information for NEXTSTELLIS.

NEXTSTELLIS (drospirenone and estetrol tablets), for oral use
Initial U.S. Approval: 2021



NEXTSTELLIS is a combination of drospirenone, a progestin, and estetrol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy.



NEXTSTELLIS may be less effective in females with a BMI ≥30 kg/m2. In females with BMI ≥30 kg/m2, decreasing effectiveness may be associated with increasing BMI.



  • Take one tablet by mouth at the same time every day.
  • Take tablets in the order directed on the blister pack.



NEXTSTELLIS consists of 28 tablets in the following order:

  • 24 pink active tablets each containing drospirenone 3 mg and estetrol 14.2 mg
  • 4 white inert tablets



  • A high risk of arterial or venous thrombotic diseases
  • Current or history of a hormonally-sensitive malignancy (e.g., breast cancer)
  • Hepatic adenoma, hepatocellular carcinoma, acute hepatitis or decompensated cirrhosis
  • Co-administration with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir
  • Abnormal uterine bleeding that has an undiagnosed etiology
  • Renal impairment
  • Adrenal insufficiency



  • Thromboembolic Disorders and Other Vascular Problems: Stop NEXTSTELLIS if a thrombotic or thromboembolic event occurs. Start no earlier than 4 weeks after delivery. Consider all cardiovascular risk factors before initiating in any female, particularly in the presence of multiple risk factors.
  • Hyperkalemia: Check serum potassium concentration during the first NEXTSTELLIS treatment cycle in females on long-term treatment with medications that may increase serum potassium concentration.
  • Hypertension: Monitor blood pressure periodically and stop use if blood pressure rises significantly.
  • Migraine: Discontinue if new, recurrent, persistent, or severe migraines occur.
  • Hormonally-Sensitive Malignancy: Discontinue NEXTSTELLIS if a hormonally-sensitive malignancy is diagnosed.
  • Liver Disease: Withhold or permanently discontinue for persistent or significant elevation of liver enzymes.
  • Glucose Tolerance and Hypertriglyceridemia: Monitor glucose in females with prediabetes or diabetes. Consider an alternate contraceptive method for females with hypertriglyceridemia.
  • Gallbladder Disease and Cholestasis: Consider discontinuing NEXTSTELLIS in females with symptomatic gallbladder or cholestatic disease.
  • Bleeding Irregularities and Amenorrhea: May cause irregular bleeding or amenorrhea. Evaluate for other causes if symptoms persist.



Most common adverse reactions (≥2%): Bleeding irregularities, mood disturbance, headache, breast symptoms, dysmenorrhea, acne, weight increased, and libido decreased



  • CYP3A Inducers: May lead to contraceptive failure and/or increase breakthrough bleeding. Avoid concomitant use. If concomitant use is unavoidable, use an alternative or back-up contraceptive method during co-administration and up to 28 days after discontinuation of the CYP3A inducer.
  • See full Prescribing Information for additional clinically significant drug interactions.



  • Pregnancy: Discontinue if pregnancy occurs.
  • Lactation: Advise postpartum females that NEXTSTELLIS can decrease milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or

See PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

BMI=body mass index; COC=combined oral contraceptive; EU=European Union; HDL=high-density lipoprotein; LDL=low-density lipoprotein; LNG=levonorgestrel.



1. Foidart JM, Gaspard U, Pequeux C, et al. Unique vascular benefits of estetrol,
a native fetal estrogen with specific actions in tissues (NEST). In: Brinton RD,
Genazzani AR, Simoncini T, Stevenson JC, eds. Sex Steroids’ Effects on Brain,
Heart and Vessels Volume 6: Frontiers in Gynecological Endocrinology. New
York, NY: Springer International Publishing; 2019:169-195.
2. NEXTSTELLIS [package insert]. Raleigh, NC: Mayne Pharma; July 2022 3. Coelingh Bennink HJT, Holinka CF, Diczfalusy E. Estetrol review: profile and
potential clinical applications. Climacteric. 2008;11(suppl 1):47-58.
4. Data on file. Clinical study report MIT-Es0001-C302. Mayne Pharma US.
Raleigh, NC.
contraceptive-301270669.html [Last accessed July 8 2022]
6. Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17ß-estradiol in
combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk
assessment. Contraception. 2013;87(6):706-727.
7. Arnal JF, Lenfant F, Metivier R, et al. Membrane and nuclear estrogen receptor
alpha actions: from tissue specificity to medical implications. Physiol Rev.
2017;97(3):1045- 1087.
8. Food and Drug Administration. FDA label database. Accessed May 21, 2021.
9. Abot A, Fontaine C, Buscato M, et al. The uterine and vascular actions of estetrol
delineate a distinctive profile of estrogen receptor a modulation, uncoupling
nuclear and membrane activation. EMBO Mol Med. 2014;6(10):1328-1346.
10. Moggs JG, Orphanides G. Estrogen receptors: orchestrators of pleiotropic cellular
responses. EMBO Rep. 2001;2(9):775-781.
11. Coelingh Bennink HJ, Heegaard AM, Visser M, Holinka CF, Christiansen C. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric. 2008;11(suppl 1):2-14.
12. Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, Visser M, Foidart JM, Gemzell-Danielsson K. Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study. Menopause. 2017;24(6):677-685.
13. Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, Visser M, Foidart JM, Gemzell-Danielsson K. Pharmacokinetics of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Climacteric. 2017;20(3):285-289.
14. Benoit T, Valera MC, Fontaine C, et al. Estetrol, a fetal selective estrogen receptor modulator, acts on the vagina of mice through nuclear estrogen receptor α activation. Am J Pathol. 2017;187(11):2499-2507.
15. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med. 2006;27(4):299-402.
16. Hyder SM, Chiappetta C, Stancel GM. Synthetic estrogen 17alpha-ethinyl estradiol induces pattern of uterine gene expression similar to endogenous estrogen 17beta-estradiol. J Pharmacol Exp Ther. 1999;290(2):740-747.